HealthDay News — Sleeve gastrectomy (SG) and Roux-en-Y gastric bypass (RYGB) are highly effective for reducing hepatic steatosis in patients with severe obesity and type 2 diabetes, with almost complete clearance of liver fat one year after surgery, according to a study published online Nov. 30 in the Annals of Internal Medicine.

Kathrine Aglen Seeberg, M.D., from the University of Oslo in Norway, and colleagues compared the one-year effects of SG and RYGB on hepatic steatosis and fibrosis in a single-center randomized controlled trial involving 100 patients with type 2 diabetes (mean body mass index, 42 kg/m2) from a tertiary care obesity center. Participants were randomly assigned in a 1:1 ratio to SG or RYGB.

The researchers found that from surgery to one-year follow-up, the decline in liver fat fraction was similar after SG and RYGB (−19.7 and −21.5 percent, respectively); at one year, almost all patients had no or low-grade steatosis (SG, 94 percent; RYGB, 100 percent). In 77 percent of patients, the enhanced liver fibrosis score category remained stable; however, at one year, 18 percent experienced worsening of fibrosis, with no substantial difference between the groups.

Continue Reading

“RYGB and SG were both highly effective in reducing hepatic steatosis in patients with type 2 diabetes mellitus,” the authors write. “Both procedures stand out as appropriate treatment options to reduce the burden of nonalcoholic fatty liver disease.”

Abstract/Full Text (subscription or payment may be required)